The FDA has approved Cablivi (caplacizumab-yhdp; Sanofi) for injection for the treatment of pediatric patients aged 12 years and older with acquired thrombotic thrombocytopenic purpura (aTTP), to be used in combination with plasma exchange and…
FDA approves caplacizumab for pediatric acquired thrombotic thrombocytopenic purpura
